US Patent

US8865688 — Compositions and methods for treatment of bowel diseases with granulated mesalamine

Method of Use · Assigned to Dr Falk Pharma GmbH · Expires 2030-05-01 · 4y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating gastrointestinal disorders, including Crohn's disease and ulcerative colitis, using a granulated mesalamine formulation.

USPTO Abstract

Disclosed are methods for treating gastrointestinal disorders, e.g., Crohn's disease, ulcerative colitis, and diverticular disease, with a granulated mesalamine formulation. Some formulations use granulated mesalamine in capsule form. Also included are methods to extend remission of ulcerative colitis by administration of a once-daily dosage of granulated mesalamine.

Drugs covered by this patent

mesalamine (MESALAMINE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1310`	—	mesalamine

Patent Metadata

Patent number: US8865688
Jurisdiction: US
Classification: Method of Use
Expires: 2030-05-01
Drug substance claim: No
Drug product claim: No
Assignee: Dr Falk Pharma GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.